MCID: DBT033
MIFTS: 21

Diabetes Mellitus, Noninsulin-Dependent, 2 malady

Categories: Genetic diseases, Endocrine diseases, Metabolic diseases

Aliases & Classifications for Diabetes Mellitus, Noninsulin-Dependent, 2

Aliases & Descriptions for Diabetes Mellitus, Noninsulin-Dependent, 2:

Name: Diabetes Mellitus, Noninsulin-Dependent, 2 54 29 13

Classifications:



External Ids:

OMIM 54 601407

Summaries for Diabetes Mellitus, Noninsulin-Dependent, 2

MalaCards based summary : Diabetes Mellitus, Noninsulin-Dependent, 2 is related to diabetes mellitus, noninsulin-dependent. An important gene associated with Diabetes Mellitus, Noninsulin-Dependent, 2 is NIDDM2 (Non Insulin Dependent Diabetes Mellitus 2). The drugs Linagliptin and Metformin have been mentioned in the context of this disorder.

Description from OMIM: 601407

Related Diseases for Diabetes Mellitus, Noninsulin-Dependent, 2

Diseases in the Diabetes Mellitus, Noninsulin-Dependent family:

Diabetes Mellitus, Noninsulin-Dependent 1 Diabetes Mellitus, Noninsulin-Dependent, 2
Diabetes Mellitus, Noninsulin-Dependent, 5 Kcnj11-Related Susceptibility to Noninsulin-Dependent Diabetes Mellitus

Diseases related to Diabetes Mellitus, Noninsulin-Dependent, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 diabetes mellitus, noninsulin-dependent 11.3

Symptoms & Phenotypes for Diabetes Mellitus, Noninsulin-Dependent, 2

Clinical features from OMIM:

601407

Drugs & Therapeutics for Diabetes Mellitus, Noninsulin-Dependent, 2

Drugs for Diabetes Mellitus, Noninsulin-Dependent, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 777)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 668270-12-0 10096344
2
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
3
Voglibose Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 83480-29-9 444020
4
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1 204656-20-2
5
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
6
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 141758-74-9 15991534
7
Glipizide Approved Phase 4,Phase 3,Phase 2,Phase 1 29094-61-9 3478
8
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 361442-04-8 11243969
9
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 111025-46-8 4829
10
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1 160337-95-1
11
Zinc Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
12
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 56180-94-0 441184
13
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
14
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1 133107-64-9
15
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
16
Insulin Detemir Approved Phase 4,Phase 3,Phase 1 169148-63-4 5311023
17
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1 93479-97-1 3476
18
Amlodipine Approved Phase 4,Phase 3,Phase 1 88150-42-9 2162
19
Atenolol Approved Phase 4 29122-68-7 2249
20
Clonidine Approved Phase 4,Phase 3 4205-90-7 2803
21
Doxazosin Approved Phase 4 74191-85-8 3157
22
Furosemide Approved, Vet_approved Phase 4,Phase 1 54-31-9 3440
23
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
24
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 138402-11-6 3749
25
Ramipril Approved Phase 4,Phase 3,Early Phase 1 87333-19-5 5362129
26
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
27
Fluvastatin Approved Phase 4 93957-54-1 1548972
28
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
29
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2 128-13-2 31401
30
Gliclazide Approved Phase 4,Phase 3,Phase 1,Phase 2 21187-98-4 3475
31
Ticlopidine Approved Phase 4,Phase 2 55142-85-3 5472
32
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1 850649-61-5 11450633
33
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
34
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1 207748-29-6
35
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2 135062-02-1 65981
36
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10238-21-8 3488
37
Vildagliptin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 274901-16-5 6918537
38
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
39
Methyltestosterone Approved Phase 4,Phase 3,Phase 2 58-18-4 6010
40
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2 58-22-0 6013
41
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
42
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2 75847-73-3 5362032 40466924
43
Enalaprilat Approved Phase 4,Phase 3,Phase 2 76420-72-9 6917719
44
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
45
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
46
Cilostazol Approved Phase 4,Phase 3 73963-72-1 2754
47
Candesartan Approved Phase 4,Phase 3,Phase 2 139481-59-7 2541
48
Oxymetazoline Approved Phase 4,Phase 1 1491-59-4 4636
49
Phenylephrine Approved Phase 4,Phase 1 59-42-7 6041
50
Ezetimibe Approved Phase 4,Phase 3,Phase 2 163222-33-1 150311

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4
2 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4
3 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
4 Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding Unknown status NCT01597531 Phase 4
5 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4
6 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4
7 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
8 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4
9 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4
10 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4
11 The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics Unknown status NCT01478776 Phase 4
12 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
13 Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy Unknown status NCT02129985 Phase 4
14 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4
15 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4
16 Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients Unknown status NCT00399204 Phase 4
17 Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes Unknown status NCT00747409 Phase 4
18 The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes Unknown status NCT02248714 Phase 4
19 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4
20 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
21 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion Unknown status NCT02406443 Phase 4
22 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4
23 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4
24 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4
25 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4
26 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4
27 Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes Unknown status NCT00736515 Phase 4
28 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4
29 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4
30 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
31 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
32 Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus Unknown status NCT00446810 Phase 4
33 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4
34 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
35 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4
36 TReatment by Insulin Continuous Infusion in Type 2 DIAbetes Unknown status NCT01889914 Phase 4
37 Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes. Unknown status NCT00254085 Phase 4
38 Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus Unknown status NCT01206647 Phase 4
39 A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes Unknown status NCT00144144 Phase 4
40 A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients Unknown status NCT00336310 Phase 4
41 Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells Unknown status NCT00523393 Phase 4
42 Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria Unknown status NCT01038895 Phase 4
43 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
44 Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes Unknown status NCT01867502 Phase 4
45 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
46 the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin Unknown status NCT02438397 Phase 4
47 Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes Unknown status NCT01978405 Phase 4
48 Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients Unknown status NCT01382303 Phase 4
49 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4
50 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4

Search NIH Clinical Center for Diabetes Mellitus, Noninsulin-Dependent, 2

Genetic Tests for Diabetes Mellitus, Noninsulin-Dependent, 2

Genetic tests related to Diabetes Mellitus, Noninsulin-Dependent, 2:

id Genetic test Affiliating Genes
1 Diabetes Mellitus, Noninsulin-Dependent, 2 29

Anatomical Context for Diabetes Mellitus, Noninsulin-Dependent, 2

Publications for Diabetes Mellitus, Noninsulin-Dependent, 2

Variations for Diabetes Mellitus, Noninsulin-Dependent, 2

Expression for Diabetes Mellitus, Noninsulin-Dependent, 2

Search GEO for disease gene expression data for Diabetes Mellitus, Noninsulin-Dependent, 2.

Pathways for Diabetes Mellitus, Noninsulin-Dependent, 2

GO Terms for Diabetes Mellitus, Noninsulin-Dependent, 2

Sources for Diabetes Mellitus, Noninsulin-Dependent, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....